

Korea's Samsung invests in Generate Biomedicines to advance AI-driven protein therapeutics discovery

18 December 2024 | News

For advancing innovation and creating a robust ecosystem for AI-enabled therapeutic development



South Korea-based Samsung has invested in Generate Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. The investment was made via the Samsung Life Science Fund, which was created jointly between Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.

Generate Biomedicines, founded by Flagship Pioneering, is a US-based clinical stage company leading in generative biology. The company applies artificial intelligence (AI)-based optimisation and *de novo* generation to discover and design novel protein therapeutics, and has a robust pipeline of approximately 20 programmes from preclinical to clinical development across oncology, immunology, and infectious diseases.

"We see great potential in Generate to develop first- and best-in-class therapeutics," said John Rim, President and CEO of Samsung Biologics. "Leveraging Generate's strengths in AI and machine learning, we look forward to creating an ecosystem for development, manufacturing, and R&D collaboration to advance next-generation medicines in areas with unmet needs."

"Funding from leading partners like Samsung enables us to continue advancing our platform, generating high-quality data, and empowering our exceptional team to tackle some of the toughest challenges in human health," said Mike Nally, CEO of Generate Biomedicines. "With clinical programs already in progress and plans to add three to six more within the next 18 months, we are turning technological promise into tangible outcomes."